GUTS
FRACTYL HEALTH, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.38
−10.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 93.0K | 120.0K | — |
| Cost of Revenue | — | — | 50.0K | 77.0K | 452.0K |
| Gross Profit | — | — | 43.0K | 43.0K | (452.0K) |
| Operating Expenses | |||||
| R&D Expense | 63.4M | 74.5M | 70.5M | 38.0M | 34.4M |
| SG&A Expense | 22.5M | 22.3M | — | — | 14.6M |
| General & Admin Expense | 10.5M | — | — | — | 15.0M |
| Selling & Marketing Expense | — | — | — | — | (452.0K) |
| Other Expenses | — | — | 23.1M | 12.8M | — |
| Total Operating Expenses | 85.9M | 96.8M | 93.6M | 50.9M | 48.9M |
| Cost and Expenses | 85.9M | 96.8M | 93.6M | 51.0M | 49.4M |
| Operating Income (EBIT) | (85.9M) | (96.8M) | (93.5M) | (50.8M) | (49.4M) |
| Non-Operating | |||||
| Interest Income | 1.4M | 1.5M | 4.1M | 1.3M | 797.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.4M | 1.5M | 4.1M | 1.3M | 797.0K |
| Other Non-Op Income/Expense | (19.8M) | (44.1M) | 24.8M | (26.3M) | 2.9M |
| Non-Operating Income (excl Interest) | 19.8M | 44.1M | (24.8M) | 26.3M | (2.9M) |
| EBT (Pre-Tax Income) | (105.7M) | (141.0M) | (68.7M) | (77.1M) | (46.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (105.7M) | (141.0M) | (68.7M) | (77.1M) | (46.5M) |
| Earnings from Cont. Ops | (105.7M) | (141.0M) | (68.7M) | (77.1M) | (46.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (105.7M) | (141.0M) | (70.4M) | (94.3M) | (63.6M) |
| Per Share | |||||
| Basic EPS | ($13.20) | ($11.04) | ($19.44) | ($23.76) | ($16.08) |
| Diluted EPS | ($13.20) | ($11.04) | ($19.44) | ($23.76) | ($16.08) |
| Revenue Per Share | $0.00 | $0.00 | $0.03 | $0.03 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 13.2M | 12.8M | 3.6M | 4.0M | 4.0M |
| Diluted Shares Outstanding | 13.2M | 12.8M | 3.6M | 4.0M | 4.0M |
| Profitability Metrics | |||||
| EBITDA | (104.5M) | (139.8M) | (68.0M) | (76.8M) | (46.0M) |
| D&A | 1.1M | 1.1M | 677.0K | 286.0K | 452.0K |
| EBIT | (105.7M) | (141.0M) | (68.7M) | (77.1M) | (46.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026